Foreword
Guidelines developed in partnership with
This resource has been developed, reviewed or revised more than five years ago. It may no longer reflect current evidence or best practice.
Published: 2015
National Health and Medical Research Council 
These guidelines (recommendations) in the web-version of this guideline were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 2 November 2015 under section 14A of the National Health and Medical Research Council Act 1992 In approving the guidelines (recommendations), NHMRC considers that they meet the NHMRC standard for clinical practice guidelines. This approval is valid for a period of five years. NHMRC is satisfied that the guidelines (recommendations) are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for health professionals practising in an Australian health care setting.
This publication reflects the views of the authors and not necessarily the views of the Australian Government.As Patron of the Prostate Cancer Foundation of Australia I am well aware of the health risks posed by prostate cancer.
Ever year almost 20,000 Australian men are diagnosed with this disease and sadly 3,300 men die of it. This makes prostate cancer the second most common cause of male cancer deaths in Australia and the fourth most common cause of male deaths overall.
Prostate cancer can affect any man, changing their lives and touching the lives of their families.
The purpose of these guidelines is to provide clear, consistent, evidence-based guidance on PSA testing and the early management of test-detected prostate cancer.
I welcome the development of these guidelines and the contribution they will make to the health and well-being of men around the nation.
Governor-General of the Commonwealth of Australia,
His Excellency General the Honourable Sir Peter Cosgrove AK MC (Retd)